AU2001276737A1 - Protein injection preparations - Google Patents

Protein injection preparations

Info

Publication number
AU2001276737A1
AU2001276737A1 AU2001276737A AU7673701A AU2001276737A1 AU 2001276737 A1 AU2001276737 A1 AU 2001276737A1 AU 2001276737 A AU2001276737 A AU 2001276737A AU 7673701 A AU7673701 A AU 7673701A AU 2001276737 A1 AU2001276737 A1 AU 2001276737A1
Authority
AU
Australia
Prior art keywords
injection preparations
protein injection
protein
preparations
injection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001276737A
Inventor
Yoshimitsu Iida
Masahiko Tanikawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of AU2001276737A1 publication Critical patent/AU2001276737A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001276737A 2000-08-04 2001-08-06 Protein injection preparations Abandoned AU2001276737A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000237432 2000-08-04
JP2000-237432 2000-08-04
PCT/JP2001/006739 WO2002011753A1 (en) 2000-08-04 2001-08-06 Protein injection preparations

Publications (1)

Publication Number Publication Date
AU2001276737A1 true AU2001276737A1 (en) 2002-02-18

Family

ID=18729296

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001276737A Abandoned AU2001276737A1 (en) 2000-08-04 2001-08-06 Protein injection preparations

Country Status (5)

Country Link
US (1) US20040038878A1 (en)
EP (1) EP1336410A4 (en)
JP (1) JP5490972B2 (en)
AU (1) AU2001276737A1 (en)
WO (1) WO2002011753A1 (en)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001240020B9 (en) * 2000-03-01 2008-12-04 Medimmune, Llc High potency recombinant antibodies and method for producing them
BRPI0110914B8 (en) † 2000-05-15 2021-05-25 Hoffmann La Roche 'liquid pharmaceutical composition, process for its preparation and use of a pharmaceutical composition'
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US20040002451A1 (en) * 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
AU2005302453A1 (en) * 2004-10-29 2006-05-11 Medimmune, Llc Methods of preventing and treating RSV infections and related conditions
AR053026A1 (en) * 2005-03-08 2007-04-18 Pharmacia & Upjohn Co Llc COMPOSITIONS OF ANTIBODIES ANTI FACTOR OF STIMULATION OF COLONIES OF MACROFAGOS (ANTI-M CSF)
CA2607663C (en) * 2005-05-19 2014-08-12 Amgen Inc. Compositions and methods for increasing the stability of antibodies
BRPI0611901A2 (en) 2005-06-14 2012-08-28 Amgen, Inc composition, lyophilized kit and process for preparing a composition
WO2007108505A1 (en) 2006-03-22 2007-09-27 Chugai Seiyaku Kabushiki Kaisha Erythropoietin solution preparation
WO2008045373A2 (en) * 2006-10-06 2008-04-17 Amgen Inc. Stable antibody formulations
ES2925992T3 (en) * 2006-10-20 2022-10-20 Amgen Inc Stable formulations of polypeptides
KR20100014674A (en) * 2007-03-29 2010-02-10 아보트 러보러터리즈 Crystalline anti-human il-12 antibodies
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
PT2197919E (en) 2007-08-27 2014-07-17 Ratiopharm Gmbh Liquid formulation of g-csf conjugate
CN101969971A (en) * 2007-11-30 2011-02-09 雅培制药有限公司 Protein formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
EP2328607A1 (en) 2008-07-16 2011-06-08 Arecor Limited Stable formulation of a therapeutic protein
PT2349314E (en) * 2008-10-21 2013-05-28 Baxter Int Lyophilized recombinant vwf formulations
CN102202682B (en) 2008-11-04 2015-08-19 Aska制药株式会社 Containing the waterborne compositions of follicle stimulating hormone
BRPI0921320A2 (en) * 2008-11-28 2018-05-22 Abbott Laboratories stable antibody compositions and methods for stabilizing them
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
US20100278822A1 (en) * 2009-05-04 2010-11-04 Abbott Biotechnology, Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
CA2726232A1 (en) * 2009-07-16 2010-08-12 Arecor Limited Stable formulation of a therapeutic protein
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
RS61082B1 (en) 2010-02-26 2020-12-31 Novo Nordisk As Stable antibody containing compositions
EP2542257B1 (en) 2010-03-01 2017-07-05 Bayer Healthcare LLC Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
RU2012153786A (en) 2010-05-28 2014-07-10 Ново Нордиск А/С STABLE MULTI-DOSE COMPOSITIONS CONTAINING ANTIBODY AND CONSERVANT
CN105854016A (en) 2010-11-11 2016-08-17 艾伯维生物技术有限公司 Improved high concentration anti-TNF[alpha] antibody liquid formulations
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US20140017318A1 (en) * 2012-07-10 2014-01-16 Kevin O'Connell Method to produce a medicinal product comprising a biologically active protein and the resulting product
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
BR112015004467A2 (en) 2012-09-02 2017-03-21 Abbvie Inc method for controlling protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EA201791717A1 (en) 2012-09-07 2018-03-30 Кохерус Байосайенсис, Инк. STABLE WATER COMPOSITIONS ADALIMUMAB
AU2013381687A1 (en) 2013-03-12 2015-09-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9480739B2 (en) 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
AR097762A1 (en) 2013-09-27 2016-04-13 Intervet Int Bv DRY FORMULATIONS OF VACCINES THAT ARE STABLE AT ENVIRONMENTAL TEMPERATURE
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2015075201A1 (en) 2013-11-21 2015-05-28 Genmab A/S Antibody-drug conjugate lyophilised formulation
TW201609145A (en) * 2013-12-25 2016-03-16 參天製藥股份有限公司 Injectable agent and depot formation method
AR099470A1 (en) 2014-02-17 2016-07-27 Intervet Int Bv LIQUID CORRAL BIRD VIRUS VACCINES
TWI670085B (en) 2014-02-19 2019-09-01 荷蘭商英特威國際公司 Swine virus vaccines that are liquid stable
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
EP3402465B1 (en) 2016-01-13 2024-03-13 Genmab A/S Formulation for antibody and drug conjugate thereof
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
CN114917185B (en) 2016-10-21 2023-11-14 美国安进公司 Pharmaceutical formulations and methods of making the same

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5920647B2 (en) * 1976-10-01 1984-05-15 武田薬品工業株式会社 injection
JP2648301B2 (en) 1983-12-27 1997-08-27 ジエネテイツクス・インスチチユ−ト・インコ−ポレ−テツド Vector containing auxiliary DNA for transformation of eukaryotic cells
JPS6197229A (en) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd Stable erythropoietin preparation
US4745099A (en) * 1985-02-06 1988-05-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of malignant tumors
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
KR100263845B1 (en) 1989-10-13 2000-08-16 스튜어트 엘.왓트 Erythropoietin isoforms and preparation method thereof and pharmaceutical composition containing it
GB9001987D0 (en) * 1990-01-29 1990-03-28 Janssen Pharmaceutica Nv Improved cyclodextrin based erythropietin formulation
JPH0565233A (en) * 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc Monoclonal antibody-containing lyophilized preparation
JPH0710753A (en) * 1993-06-25 1995-01-13 Taisho Pharmaceut Co Ltd Injection preparation
IL192290A0 (en) 1993-08-17 2008-12-29 Kirin Amgen Inc Erythropoietin analogs
AU707796B2 (en) * 1995-03-21 1999-07-22 Merck Serono Sa HCG liquid formulations
US5656730A (en) * 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
JPH08333277A (en) * 1995-06-05 1996-12-17 Hoechst Japan Ltd Stabilized aqueous solution formulation of human blood coagulating xiii-th factor
JPH09241178A (en) * 1996-03-07 1997-09-16 Takeda Chem Ind Ltd Production of sustained release pharmaceutical preparation of adenocorticotropic hormone derivative
TW518219B (en) * 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
JP3723857B2 (en) * 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 Aqueous pharmaceutical composition containing human growth hormone
EP1060746A4 (en) * 1998-03-06 2002-06-19 Chugai Pharmaceutical Co Ltd Protein-free preparations

Also Published As

Publication number Publication date
EP1336410A1 (en) 2003-08-20
EP1336410A4 (en) 2005-10-12
WO2002011753A1 (en) 2002-02-14
US20040038878A1 (en) 2004-02-26
JP5490972B2 (en) 2014-05-14

Similar Documents

Publication Publication Date Title
AU2001276737A1 (en) Protein injection preparations
AU2001232799A1 (en) Protein c derivatives
AU2001236005A1 (en) Preparations stabilized over long time
AU2001294192A1 (en) Solid preparations
AU2001277781A1 (en) Stabilized antibody-containing preparations
AU2001273164A1 (en) Membrane associated protein zupari
AU6045900A (en) Interaction-activated proteins
AU2001282607A1 (en) Solution preparations stabilized over long time
AU2001234893A1 (en) Protein mapping
AU2001242479A1 (en) Proliposomal encapsulated preparations
AU2001286721A1 (en) Human interleukin-four induced protein
AU2001259450A1 (en) Cytoskeleton-associated proteins
AU2001288102A1 (en) Solid preparations
AU2001282521A1 (en) OCT preparations
AU2001272427A1 (en) Solid preparations
AU2001244863A1 (en) Apoptin-associating protein
AU2002239747A1 (en) Cystoskeleton-associated proteins
AU2001250585A1 (en) Insecticidal peptides and methods for using same
AU3506800A (en) Leukocyte- and blood-associated proteins
AU2002243234A1 (en) Embryogenesis associated proteins
AU1540701A (en) Novel protein
AU2001278777A1 (en) Irap-binding protein
AU2001278975A1 (en) Alpha-conotoxin peptides
AU2002240889A1 (en) Proteins that interact with betatrcp
AU7304600A (en) Novel protein